CellCept

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved February 1998

Specific Treatments:

prevention of organ rejection inpatients undergoing heart transplants

Find Related Trials for The Following Conditions

General Information

CellCept when used in combination with cyclosporine and corticosteroids has been approved for the prevention of organ rejection inpatients undergoing heart transplants. CellCept has previously been approved for the prevention of organ rejection in kidney-transplant patients.

Side Effects

The principal adverse reactions associated with the administration of Cell Cept include diarrhea, leukopenia (reduction of white blood cells), sepsis, and vomiting, and there is evidence of a higher frequency of certain types of infections.